Clamikalant sodium_product_DataBase

Bioactivity	Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia[1].
Invitro	Clamikalant sodium (HMR 1098; 40 μM) prevents improvement effect of Levosimendam on left ventricular developed pressure (LVDP) recovery rate, abolishes the inhibitory effect of Levosimendan on hypothermic preservation-induced activation of calpain, cleavage of Bid, and apoptosis[2].Clamikalant sodium (HMR 1098; 30 µM, 24 hours) reduces cellular viability, increases the apoptosis of Neonatal rat cardiomyocytes (NRCs) [3].Clamikalant sodium (30 µM) decreases the Bcl-2 protein level and increases the Bax protein level in the LPS-exposed NRCs[3]. Cell Viability Assay[3] Cell Line:
In Vivo	Clamikalant sodium (HMR 1098; 6.0 mg/kg; 5 min prior to EET administration) completely abolishes the cardioprotection produced by epoxyeicosatrienoic acid (EET)[1].
Name	Clamikalant sodium
CAS	261717-22-0
Formula	C19H21ClN3NaO5S2
Molar Mass	493.96
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Garrett J Gross, et al. Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts. J Mol Cell Cardiol. 2013 Ju [2]. Hai-yan Zhou, et al. Improved myocardial function with supplement of levosimendan to Celsior solution. J Cardiovasc Pharmacol. 2014 Sep;64(3):256-65. [3]. Xiaohui Zhang, et al. Sarcolemmal ATP-sensitive potassium channel protects cardiac myocytes against lipopolysaccharide-induced apoptosis. Int J Mol Med. 2016 Sep;38(3):758-66.

PeptideDB

Clamikalant sodium

CAS: 261717-22-0 F: C19H21ClN3NaO5S2 W: 493.96